AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Go back to AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation| AbbVie (NYSE: ABBV) | Delayed: 264.96 +3.13 (1.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $261.83 | 52 Week High | $68.12 | |||
| Open | $260.70 | 52 Week Low | $50.71 | |||
| Day High | $266.84 | P/E | 57.48 | |||
| Day Low | $260.10 | EPS | $4.61 | |||
| Volume | 5,157,114 | |||||
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 13.47 +0.34 (2.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.13 | 52 Week High | $34.49 | |||
| Open | $13.27 | 52 Week Low | $20.39 | |||
| Day High | $13.70 | P/E | N/A | |||
| Day Low | $13.09 | EPS | $-3.18 | |||
| Volume | 335,247 | |||||
